Home › Research › Disease mechanisms
A review on recent advances in Alzheimer's disease: The role of synaptic plasticity
Nour Ibrahim Kenaan, Zuheir Alshehabi. AIMS neuroscience, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's Disease (AD) remains a significant global health challenge, characterized by progressive neurodegeneration and a decline in cognitive abilities such as memory and learning. Despite being the main cause of dementia worldwide, the precise mechanisms that underlie neuronal dysfunction and synaptic plasticity impairment in AD remain elusive. However, while genetic mutations, dietary factors, and immune dysregulation are implicated in AD pathogenesis, the current therapeutic approaches are largely centered around acetylcholinesterase inhibitors (AChEIs). Nevertheless, this cholinergic hypothesis of AD is no longer satisfactory in describing this disease and has demonstrated a limited efficacy. Hence, new treatment approaches should be developed, and that requires us to view AD from a new perspective. Herein, in our review, we present the latest studies that discussed possible AD pathologies and pharmacotherapies. Additionally, we highlight that the emerging treatments that precisely targets brain regions associated with enhancing neuroplasticity have delivered promising results and seem to be more effective than older treatments. Finally, by viewing AD as a complex interplay of various factors that ultimately cause synaptic dysfunction and cognitive decline, we can develop more effective therapeutic interventions and ultimately alleviate the significant burden of this debilitating disease for both patients and their families.
What this study adds
Evidence grade: Low
This review states that the cholinergic hypothesis is no longer satisfactory and that current treatments such as acetylcholinesterase inhibitors have limited efficacy, while emerging treatments targeting brain regions involved in neuroplasticity have shown promising results. It does not report a cure or proven new treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kenaan, N. I., & Alshehabi, Z. (2025). A review on recent advances in Alzheimer's disease: The role of synaptic plasticity. AIMS neuroscience. https://doi.org/10.3934/neuroscience.2025006
Vancouver
Kenaan NI, Alshehabi Z. A review on recent advances in Alzheimer's disease: The role of synaptic plasticity. AIMS neuroscience. 2025. doi:10.3934/neuroscience.2025006. PMID: 40717739.
BibTeX
@article{kenaan2025-40717739,
author = {Kenaan, Nour Ibrahim and Alshehabi, Zuheir},
title = {{A review on recent advances in Alzheimer's disease: The role of synaptic plasticity}},
journal = {AIMS neuroscience},
year = {2025},
doi = {10.3934/neuroscience.2025006},
pmid = {40717739},
url = {https://doi.org/10.3934/neuroscience.2025006}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Alzheimer's Disease (AD) remains a significant global health challenge, characterized by progressive neurodegeneration and a decline in cognitive abilities such as memory and learning.
- Nevertheless, this cholinergic hypothesis of AD is no longer satisfactory in describing this disease and has demonstrated a limited efficacy.
- Additionally, we highlight that the emerging treatments that precisely targets brain regions associated with enhancing neuroplasticity have delivered promising results and seem to be more effective than older treatments.
- Finally, by viewing AD as a complex interplay of various factors that ultimately cause synaptic dysfunction and cognitive decline, we can develop more effective therapeutic interventions and ultimately alleviate the significant burden of this debilitating disease for both patients and their families.
Why it matters
This review states that the cholinergic hypothesis is no longer satisfactory and that current treatments such as acetylcholinesterase inhibitors have limited efficacy, while emerging treatments targeting brain regions involved in neuroplasticity have shown promising results. It does not report a cure or proven new treatment.
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (AIMS neuroscience) |
| Journal's citation record | 0 / 4 | AIMS neuroscience: journal h-index 31 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Zuheir Alshehabi: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Latakia University: institution h-index 87 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40717739) |
| Free to read | 2 / 2 | Free to read |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3934/neuroscience.2025006
- PubMed: 40717739
- Original source →
- Free full text: AIMS neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Disease mechanisms from nearby years
Also in Disease mechanisms
138 studies in the library are filed under Disease mechanisms with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Disease mechanisms hub.